Philip G Jones Selected Research

SEP-363856

1/2024	TAAR1 Agonists Improve Glycemic Control, Reduce Body Weight and Modulate Neurocircuits Governing Energy Balance and Feeding.
1/2022	Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
10/2019	SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip G Jones Research Topics

Disease

42	Myocardial Infarction 01/2024 - 06/2006
20	Heart Failure 05/2024 - 08/2005
7	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 07/2006
7	Acute Coronary Syndrome 10/2017 - 09/2005
7	Diabetes Mellitus 09/2017 - 04/2010
6	Coronary Disease (Coronary Heart Disease) 04/2024 - 01/2004
6	Stroke (Strokes) 01/2024 - 01/2013
6	Heart Arrest (Cardiac Arrest) 01/2023 - 09/2009
5	Ischemia 01/2023 - 07/2008
5	Type 2 Diabetes Mellitus (MODY) 01/2022 - 09/2005
4	Unstable Angina 01/2023 - 10/2015
4	Hemorrhage 01/2021 - 01/2013
4	Stable Angina 01/2020 - 05/2013
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 04/2008
4	Hyperglycemia 10/2014 - 02/2008
3	Schizophrenia (Dementia Praecox) 01/2024 - 10/2019
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2024 - 09/2005
3	Atrial Fibrillation 01/2021 - 08/2017
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020 - 10/2008
3	Hypertension (High Blood Pressure) 12/2019 - 09/2005
3	Pain (Aches) 09/2007 - 08/2006
2	Weight Gain 01/2024 - 01/2002
2	Obesity 01/2024 - 09/2005
2	Peripheral Arterial Disease 01/2024 - 12/2019
2	Transient Ischemic Attack 01/2024 - 12/2019
2	Out-of-Hospital Cardiac Arrest 05/2022 - 11/2010
2	Chronic Renal Insufficiency 01/2022 - 01/2020
2	Kidney Diseases (Kidney Disease) 01/2022 - 07/2009
2	Left Ventricular Dysfunction 12/2019 - 01/2016
2	Hypoglycemia (Reactive Hypoglycemia) 07/2012 - 02/2008
2	Ventricular Fibrillation 01/2012 - 09/2009
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 02/2003 - 01/2002
1	Body Weight (Weight, Body) 01/2024
1	Malnutrition (Nutritional Deficiencies) 01/2022
1	Chronic Limb-Threatening Ischemia 01/2022
1	COVID-19 12/2021
1	Embolism (Embolus) 01/2021
1	Disease Progression 12/2020
1	Heart Diseases (Heart Disease) 10/2019
1	Neurobehavioral Manifestations 10/2019
1	Aortic Valve Stenosis (Aortic Stenosis) 01/2019

Drug/Important Bio-Agent (IBA)

8	Glucose (Dextrose)FDA LinkGeneric 02/2024 - 09/2005
4	LipidsIBA 01/2020 - 01/2004
4	Hemoglobins (Hemoglobin)IBA 12/2017 - 10/2014
3	SEP-363856IBA 01/2024 - 10/2019
3	Angiotensin Receptor AntagonistsIBA 01/2022 - 09/2005
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022 - 09/2005
3	Indicators and Reagents (Reagents)IBA 10/2015 - 01/2004
3	Nitroglycerin (Dynamite)FDA LinkGeneric 11/2014 - 05/2013
3	Ranolazine FDA Link 11/2014 - 05/2013
3	Blood Glucose (Blood Sugar)IBA 08/2013 - 03/2009
2	SodiumIBA 02/2024 - 10/2014
2	Antipsychotic Agents (Antipsychotics)IBA 01/2024 - 10/2019
2	Trace amine-associated receptor 1IBA 01/2024 - 01/2022
2	OzoneIBA 05/2022 - 01/2019
2	Particulate MatterIBA 05/2022 - 01/2019
2	Clopidogrel (Plavix)FDA Link 12/2019 - 01/2013
2	Prasugrel Hydrochloride FDA Link 12/2019 - 01/2013
2	Mineralocorticoid Receptor AntagonistsIBA 12/2017 - 01/2014
2	Insulin (Novolin)FDA Link 08/2013 - 03/2009
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 05/2012 - 04/2010
2	PPAR alphaIBA 09/2010 - 10/2008
2	Eplerenone (Inspra)FDA LinkGeneric 01/2009 - 04/2007
2	LDL CholesterolIBA 07/2006 - 01/2004
2	LDL Lipoproteins (beta Lipoproteins)IBA 07/2006 - 01/2004
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2002 - 01/2002
1	SymportersIBA 04/2024
1	CorticosteroneIBA 01/2024
1	Triglycerides (Triacylglycerol)IBA 01/2024
1	4- (3- fluoro- 2- methylphenyl)- 4,5- dihydrooxazol- 2- ylamineIBA 01/2024
1	Olanzapine (Zyprexa)FDA Link 01/2024
1	RO5166017IBA 01/2024
1	5-HT1A Serotonin ReceptorIBA 01/2022
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022
1	Warfarin (Coumadin)FDA LinkGeneric 01/2021
1	Dabigatran FDA Link 01/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 12/2020
1	DiureticsIBA 12/2020
1	TicagrelorIBA 12/2019
1	Phencyclidine (Angel Dust)IBA 10/2019
1	Chlorpromazine (Thorazine)FDA Link 10/2019
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 10/2019
1	AnticoagulantsIBA 05/2018

Therapy/Procedure

23	Therapeutics 05/2024 - 01/2002
11	Percutaneous Coronary Intervention 01/2024 - 10/2011
8	Patient Readmission 01/2017 - 01/2009
4	Secondary Prevention 01/2020 - 03/2009
4	Stents 12/2016 - 06/2006
3	Conservative Treatment 04/2024 - 01/2022
3	Glycemic Control 01/2024 - 12/2006
3	Resuscitation 01/2017 - 09/2009
3	Drug-Eluting Stents 12/2016 - 06/2006
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2024 - 01/2020
2	Surgical Amputation (Amputations) 01/2022 - 10/2015
2	Ambulatory Care (Outpatient Care) 12/2021 - 01/2016
2	Transcatheter Aortic Valve Replacement 12/2019 - 01/2019
2	Cardiac Rehabilitation 01/2019 - 12/2016
2	Transplantation 01/2016 - 05/2015
2	Heart-Assist Devices 01/2016 - 05/2015